KindlyMD (NASDAQ:NAKA) Price Target Raised to $13.00

Posted by George Bondi on Sep 25th, 2026

KindlyMD (NASDAQ:NAKA – Free Report) had its target price boosted by B. Riley Financial from $11.00 to $13.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other research analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of KindlyMD in a research note on Friday, August 7th. TD Cowen lifted their price objective on shares of KindlyMD from $1.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, July 27th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $20.00.

Read Our Latest Research Report on NAKA

KindlyMD Trading Up 6.2%

Shares of NASDAQ:NAKA opened at $9.76 on Tuesday. The firm’s 50 day moving average is $6.53 and its two-hundred day moving average is $6.75. The firm has a market capitalization of $174.70 million, a P/E ratio of -0.27 and a beta of 15.99. KindlyMD has a 52 week low of $3.33 and a 52 week high of $53.20.

KindlyMD (NASDAQ:NAKA – Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share (EPS) for the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%.The business had revenue of $35.87 million for the quarter. Analysts predict that KindlyMD will post -12.94 EPS for the current year.

Insider Buying and Selling at KindlyMD

In other news, CEO David F. Bailey bought 4,852 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was acquired at an average price of $6.27 per share, with a total value of $30,422.04. Following the completion of the purchase, the chief executive officer directly owned 3,185,246 shares of the company’s stock, valued at $19,971,492.42. This represents a 0.15% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders acquired a total of 41,904 shares of company stock valued at $235,231 in the last ninety days. Corporate insiders own 24.49% of the company’s stock.

Institutional Investors Weigh In On KindlyMD

Hedge funds and other institutional investors have recently bought and sold shares of the business. J. Derek Lewis & Associates Inc. acquired a new stake in KindlyMD in the 4th quarter valued at about $167,000. Hunting Hill Global Capital LLC acquired a new position in shares of KindlyMD in the 4th quarter worth approximately $4,672,000. Arrington Capital Management LLC bought a new stake in shares of KindlyMD in the 4th quarter worth approximately $1,028,000. Waddell & Associates LLC bought a new stake in shares of KindlyMD in the 4th quarter worth approximately $201,000. Finally, Yorkville Advisors Global LP acquired a new stake in KindlyMD during the fourth quarter valued at approximately $3,265,000.

About KindlyMD

(Get Free Report)

KindlyMD, Inc is a healthcare company focused on providing integrated care for patients with complex medical needs, including chronic pain and substance use disorders. Its care model combines primary care, behavioral health services and medication-assisted treatment, with an emphasis on coordinated, patient-centered treatment.

The company has operated clinics in Utah and has also used telehealth and other technology-enabled services to expand access to care. KindlyMD’s services are designed to support patients through ongoing treatment and recovery rather than addressing individual medical issues in isolation.

KindlyMD became a publicly traded company through a business combination involving Nakamoto Holdings, with its common stock trading on the Nasdaq under the symbol NAKA.